止咳散加减治疗老年肺炎的临床效果及安全性分析

Analysis of clinical effect and safety of modified Zhike Powder in the treatment of senile pneumonia

目的探析止咳散加减治疗老年肺炎的临床效果及安全性。方法98例老年肺炎患者,随机分为对照组和观察组,每组49例。对照组采用常规对症治疗,观察组在常规对症治疗基础上加用止咳散加减治疗。比较两组患者临床疗效、治疗指标(退热时间、止咳时间、祛痰时间、住院时间)、血清炎症因子(肿瘤坏死因子-α、白细胞介素-6、超敏C反应蛋白)水平、不良事件发生情况。结果对照组中显效13例,有效26例,无效10例,总有效率为79.59%(39/49);观察组中显效17例,有效30例,无效2例,总有效率为95.92%(47/49)。观察组临床总有效率高于对照组(P<0.05)。观察组患者退热时间(1.70±0.49)d、止咳时间(2.57±0.68)d、祛痰时间(4.12±1.02)d、住院时间(5.78±1.27)d均短于对照组的(4.18±0.92)、(3.74±0.81)、(5.75±1.44)、(11.95±2.62)d(P<0.05)。治疗后,观察组肿瘤坏死因子-α(1.12±0.32)ng/L、白细胞介素-6(5.41±1.18)pg/L、超敏C反应蛋白(8.87±2.25)mg/L均低于对照组的(1.60±0.38)ng/L、(9.48±1.48)pg/L、(12.34±2.47)mg/L(P<0.05)。观察组不良事件发生率6.12%(3/49)低于对照组的20.41%(10/49)(P<0.05)。结论老年肺炎患者在使用止咳散加减治疗后效果显著,症状改善时间较短,炎性反应明显降低,用药安全性较高,值得临床推广。

Objective To explore the clinical effect and safety of Zhike Powder in the treatment of senile pneumonia.Methods 98 senile patients with pneumonia were randomly divided into a control group and an observation,with 49 patients in each group.The control group was treated with routine symptomatic treatment,and the observation group was treated with modified Zhike Powder.The clinical efficacy,treatment index(fever reduction time,cough relief time,expectorant time,hospital stay),serum inflammatory factor(tumor necrosis factor-α,interleukin-6 and hypersensitive C-reactive protein)levels and incidence of adverse events were compared between the two groups.Results In the control group,13 cases were significantly effective,26 cases were effective,10 cases were ineffective,and the total effective rate was 79.59%(39/49).In the observation group,17 cases were significantly effective,30 cases were effective and 2 cases were ineffective,and the total effective rate was 95.92%(47/49).The total clinical effective rate of the observation group was higher than that of the control group(P<0.05).In the observation group,the fever reduction time was(1.70±0.49)d,the cough relief time was(2.57±0.68)d,the expectorant time was(4.12±1.02)d,and the hospital stay was(5.78±1.27)d,which were shorter than(4.18±0.92),(3.74±0.81),(5.75±1.44),and(11.95±2.62)d in the control group(P<0.05).After treatment,the tumor necrosis factor-αof the observation group was(1.12±0.32)ng/L,the interleukin-6 was(5.41±1.18)pg/L,and the hypersensitive C-reactive protein was(8.87±2.25)mg/L,which were lower than(1.60±0.38)ng/L,(9.48±1.48)pg/L,and(12.34±2.47)mg/L of the control group(P<0.05).The incidence of adverse events in the observation group was 6.12%(3/49),which was lower than 20.41%(10/49)in the control group(P<0.05).Conclusion Modified Zhike Powder shows significant effect on senile patients with pneumonia,the time of symptom improvement is short,the inflammatory reaction is significantly reduced,and the safety after treatment is high,which is worthy of clinical promotion.